Suppr超能文献

相似文献

2
Differentiation of cyclooxygenase 1- and 2-derived prostanoids in mouse kidney and aorta.
Hypertension. 2006 Aug;48(2):323-8. doi: 10.1161/01.HYP.0000231934.67549.b7. Epub 2006 Jun 26.
3
Prostaglandins and renal damage.
J Am Soc Nephrol. 1996 Aug;7(8):1245-6. doi: 10.1681/ASN.V781245.
4
Cyclooxygenase 1 and 2 in rheumatic disease: implications for nonsteroidal anti-inflammatory drug therapy.
Semin Arthritis Rheum. 1996 Aug;26(1):435-46. doi: 10.1016/s0049-0172(96)80024-2.
5
Cyclooxygenase-2 selective inhibitors and the kidney.
Curr Opin Crit Care. 2001 Dec;7(6):393-400. doi: 10.1097/00075198-200112000-00005.
6
Selective targeting of cyclooxygenase-2 reveals its role in renal medullary interstitial cell survival.
Am J Physiol. 1999 Sep;277(3):F352-9. doi: 10.1152/ajprenal.1999.277.3.F352.
7
Distinct roles for cyclooxygenases 1 and 2 in interleukin-1-induced behavioral changes.
J Pharmacol Exp Ther. 2002 Sep;302(3):1031-6. doi: 10.1124/jpet.102.036640.
8
Lithium treatment inhibits renal GSK-3 activity and promotes cyclooxygenase 2-dependent polyuria.
Am J Physiol Renal Physiol. 2005 Apr;288(4):F642-9. doi: 10.1152/ajprenal.00287.2004. Epub 2004 Dec 7.
9
Cyclooxygenase 2 and the kidney.
Curr Opin Nephrol Hypertens. 2001 Jan;10(1):89-98. doi: 10.1097/00041552-200101000-00014.
10
Renal hemodynamic effect of cyclooxygenase 2 inhibition in young men and women with uncomplicated type 1 diabetes mellitus.
Am J Physiol Renal Physiol. 2008 Jun;294(6):F1336-41. doi: 10.1152/ajprenal.00574.2007. Epub 2008 Apr 9.

引用本文的文献

1
Evaluating the Role of Aspirin in Liver Disease: Efficacy, Safety, Potential Benefits and Risks.
Life (Basel). 2024 Dec 23;14(12):1701. doi: 10.3390/life14121701.
2
Degree of Cyclooxygenase-2 Inhibition Modulates Blood Pressure Response to Celecoxib and Naproxen.
medRxiv. 2024 May 31:2024.05.30.24308244. doi: 10.1101/2024.05.30.24308244.
3
Prostanoids in Cardiac and Vascular Remodeling.
Arterioscler Thromb Vasc Biol. 2024 Mar;44(3):558-583. doi: 10.1161/ATVBAHA.123.320045. Epub 2024 Jan 25.
5
Drugs for the prevention and treatment of COVID-19 and its complications: An update on what we learned in the past 2 years.
Front Pharmacol. 2022 Oct 10;13:987816. doi: 10.3389/fphar.2022.987816. eCollection 2022.
6
Hypertension in chronic kidney disease: What lies behind the scene.
Front Pharmacol. 2022 Oct 11;13:949260. doi: 10.3389/fphar.2022.949260. eCollection 2022.
7
Inflammatory signalling in atrial cardiomyocytes: a novel unifying principle in atrial fibrillation pathophysiology.
Nat Rev Cardiol. 2023 Mar;20(3):145-167. doi: 10.1038/s41569-022-00759-w. Epub 2022 Sep 15.
8
Kidney Angiotensin in Cardiovascular Disease: Formation and Drug Targeting.
Pharmacol Rev. 2022 Jul;74(3):462-505. doi: 10.1124/pharmrev.120.000236.
10
Kidney damage from nonsteroidal anti-inflammatory drugs-Myth or truth? Review of selected literature.
Pharmacol Res Perspect. 2021 Aug;9(4):e00817. doi: 10.1002/prp2.817.

本文引用的文献

1
The coxibs, selective inhibitors of cyclooxygenase-2.
N Engl J Med. 2001 Aug 9;345(6):433-42. doi: 10.1056/NEJM200108093450607.
2
Why there are two cyclooxygenase isozymes.
J Clin Invest. 2001 Jun;107(12):1491-5. doi: 10.1172/JCI13271.
3
Physiological regulation of cyclooxygenase-2 in the kidney.
Am J Physiol Renal Physiol. 2001 Jul;281(1):F1-11. doi: 10.1152/ajprenal.2001.281.1.F1.
4
Regulated formation of eicosanoids.
J Clin Invest. 2001 Jun;107(11):1347-51. doi: 10.1172/JCI13241.
8
Cyclooxygenase 2 and the kidney.
Curr Opin Nephrol Hypertens. 2001 Jan;10(1):89-98. doi: 10.1097/00041552-200101000-00014.
9
Genetic deletion of COX-2 prevents increased renin expression in response to ACE inhibition.
Am J Physiol Renal Physiol. 2001 Mar;280(3):F449-56. doi: 10.1152/ajprenal.2001.280.3.F449.
10
Role of EP(2) and EP(3) PGE(2) receptors in control of murine renal hemodynamics.
Am J Physiol Heart Circ Physiol. 2001 Jan;280(1):H327-33. doi: 10.1152/ajpheart.2001.280.1.H327.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验